Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Spinal Cord Injury.
10.3340/jkns.2015.57.2.73
- Author:
Alp Ozgun BORCEK
1
;
Soner CIVI
;
Ozgur OCAL
;
Ozlem GULBAHAR
Author Information
1. Department of Neurosurgery, Gazi University Faculty of Medicine, Ankara, Turkey. alpborcek@gmail.com
- Publication Type:Original Article
- Keywords:
Adalimumab;
Spinal cord injury;
Tumor necrosis factor alpha
- MeSH:
Adult;
Aneurysm;
Animals;
Humans;
Lipid Peroxidation;
Male;
Malondialdehyde;
Rats;
Rats, Wistar;
Spinal Cord;
Spinal Cord Injuries*;
Tumor Necrosis Factor-alpha*;
Adalimumab;
Infliximab
- From:Journal of Korean Neurosurgical Society
2015;57(2):73-76
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Tumor necrosis factor alpha (TNF-alpha) have proven effects in pathogenesis of neuroinflammation after spinal cord injury (SCI). Current study is designed to evaluate the effects of an anti-TNF-alpha agent, adalimumab, on spinal cord clip compression injury in rats. METHODS: Thirty two male adult Wistar rats were divided into four groups (sham, trauma, infliximab, and adalimumab groups) and SCI was introduced using an aneurysm clip. Animals in treatment groups received 5 mg/kg subcutaneous adalimumab and infliximab right after the trauma. Malondialdehyde (MDA) levels were studied in traumatized spinal cord tissues 72 hours after the injury as a marker of lipid peroxidation. RESULTS: Animals that received anti-TNF-alpha agents are found to have significantly decreased MDA levels. MDA levels were significantly different between the trauma and infliximab groups (p<0.01) and trauma and adalimumab groups (p=0.022). There was no significant difference in neurological evaluation of the rats using Tarlov scale. CONCLUSION: These results suggest that, like infliximab, adalimumab has favorable effects on lipid peroxidation induced by spinal cord trauma in rats.
